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Monoclonal antibodies are typically glycosylated at asparagine residues in the Fc domain, and
glycosylation heterogeneity at the Fc sites is well known. This paper presents a method for
rapid analysis of glycosylation profile of the therapeutic monoclonal antibody trastuzumab
from different production batches using electrospray quadrupole ion-mobility time-of-flight
mass spectrometry (ESI-Q-IM-TOF). The global glycosylation profile for each production batch
was obtained by a fast LC-MS analysis, and comparisons of the glycoprofiles of trastuzumab
from different lots were made based on the deconvoluted intact mass spectra. Furthermore, the
heterogeneity at each glycosylation site was characterized at the reduced antibody level and at
the isolated glycopeptide level. The glycosylation site and glycan structures were confirmed by
performing a time-aligned-parallel fragmentation approach using the unique dual-collision
cell design of the instrument and the incorporated ion-mobility separation function. Four
different production batches of trastuzumab were analyzed and compared in terms of global
glycosylation profiles as well as the heterogeneity at each glycosylation site. The results show
that each batch of trastuzumab shares the same types of glycoforms but relative abundance of
each glycoforms is varied. (J Am Soc Mass Spectrom 2009, 20, 2021–2033) © 2009 American
Society for Mass SpectrometryMonoclonal antibodies (MABs) are an upcom-ing group of disease-modifying drugs. Theirefficacy results from specificity and inhibition
of the target antigen and from biological activities
(effector functions) activated by immune complexes
formed. MABs are used to treat cancer, auto-immune
diseases, and systemic infections [1]. Trastuzumab
(Herceptin) is a humanized monoclonal immunoglobu-
lin -1 (IgG1) antibody directed against the HER2/neu
receptor, which is over-expressed in about 25% of all
breast cancer patients [2, 3].
An IgG1 molecule consists of two identical heavy
chains and two identical light chains that are connected
to each other by four disulfide bonds. Each light chain
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doi:10.1016/j.jasms.2009.07.017additionally contains two intra-chain disulfide bonds
and each heavy chain four intra-chain disulfide bonds
leading to 16 disulfide bonds for the entire protein.
Asparagine at position 297 in the heavy chains is
N-glycosylated and heterogeneity in this glycosylation
profile is common for IgG antibodies [4, 5]. The most
common glycan structures for IgG possess zero, one, or
two terminal galactose (G) residues with or without a
fucose (F) and are defined as G0, G0F, G1F, and G2F [6, 7].
All antibody therapeutics that are currently licensed
have been produced by mammalian cell culture, utiliz-
ing Chinese hamster ovary (CHO) cells or mouse NSO
or Sp2/0 plasma cell lines [4]. Trastuzumab is produced
in CHO cells. The efficacy of a MAB is critically depen-
dent on appropriate post-translational modifications,
and each production vehicle produces different profiles
as post-translation modifications show species, tissue,
and site specificity. In vitro studies have established
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propriate glycosylation of the antibody molecule [4].
Additionally glycosylation can influence clearance and
immunogenicity of the MAB [5, 8]. Therefore, FDA
requires analytical characterization of MABs [9] and a
consistent human-type glycosylation of the MABs. Elu-
cidation of the produced glycosylation structure is thus
pivotal for the pharmaceutical industry.
Several techniques have been published about the
analysis of the glycosylation profile. In early years the
MABs were deglycosylated and analyzed with, e.g., 1H
NMR [10], sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) [11], hydrophobic interac-
tion chromatography [11], and high-pH anion-exchange
chromatography with pulsed amperometric detection
(HPAEC-PAD) [12]. Radio labeling of the released
glycans, and analyzing them by a combination of paper
electrophoresis and gel-filtration chromatography [13],
with normal phase high-performance liquid chroma-
tography (HPLC) [14, 15] or anion-exchange HPLC [16]
coupled with a fluorescence detector have also been
described. Additionally, capillary electrophoresis cou-
pled with different detectors has been described [17–
19]. More recently, several methods using mass spec-
trometry (MS) have been developed. These analyses are
performed using HPLC coupled with either electros-
pray ionization single quadruple mass spectrometry
(ESI-MS) [20, 21], or ESI quadruple time-of-flight MS
(ESI-Q-TOF-MS) [8, 22–24], or ESI orthogonal accele-
ration time-of-flight MS (ESI-oa-TOF-MS) [6, 25, 26].
Matrix assisted laser desorption/ionization-TOF-MS
(MALDI-TOF-MS) is also a widely applied technique
[14, 22, 27–29]. Most of these methods analyze the intact
or reduced MAB or tryptic digest of MAB. The gener-
ated ESI mass spectra are deconvoluted, and the accu-
rate masses of the found peaks are compared with the
theoretical masses of MABs with the most common
glycans. However, these methods are not capable of
performing true structural elucidation of the glycan
moieties as they only measure the masses of the subunit
or peptides and compare them against the masses of
known protein sequence and most common glycans.
Tandem mass spectrometry is a method of choice for
structural elucidation of glycans in terms of composi-
tion, sequence, linkage, and branching. Published re-
ports for structural elucidation generally involve an
enzymatic digestion or a chemical deglycosylation step
to obtain either glycopeptides or released glycans for
subsequent analysis using HPLC coupled with ESI-Q-
TOFMS, ESI-ion trap MS [30–32], ESI triple quadrupole
MS [33], or linear ion trap Fourier transform MS (LTQ-
FTMS) [34]. Nevertheless, these methods are time con-
suming, requiring high-resolution separation of the
peptides and glycans on the HPLC system, and/or long
separation time. In addition, for LC-MS analysis of
released glycans, due to the low ionization efficiency
and hydrophilicity imposed by the chemical nature
of the oligosaccharides, derivatization is often appl-
ied leading to time consuming sample preparations.Sinha et al. [35] compared various sample preparation
schemes coupled with a HPLC-ESI-Q-TOF MS and
compared two production lots of a recombinant mono-
clonal IgG1 antibody. Direct analysis of glycopeptides
by tandem mass spectrometry (MS/MS) represents a
rapid and sensitive method to obtain site-specific char-
acterization on glycosylation. It can provide informa-
tion on glycan structure, glycan attachment site, and
peptide sequence within one single experiment. How-
ever, direct fragmentation of glycopeptides normally
generates very complex mass spectra, which contain
fragment peaks from the intact or truncated glycan
chains as well as the deglycosylated peptide backbones
(after the complete loss of glycan chain). This heteroge-
neity, together with the superimposition of various
charge states, makes the MS/MS spectra interpretation
rather difficult. As a result, the successful application of
this approach to the site-specific glycosylation is rather
limited.
In this paper, we present a LC-MS method to distin-
guish the lot-to-lot heterogeneity of the commercially
available monoclonal antibody trastuzumab (Hercep-
tin) by a quadrupole ion-mobility time-of-flight mass
spectrometer (ESI-Q-IM-TOF-MS). Four different pro-
duction batches of trastuzumab were analyzed and
compared. To establish a global view of the IgG iso-
forms, the intact MAB proteins were first analyzed
using on-line LC/MS. Then subunits of the intact MABs
were analyzed after reduction, to confirm the heteroge-
neity of the glycoforms at the heavy chain of trastu-
zumab. On the basis of analysis of global glycoprofile,
detailed characterization of the glycans was performed
using a bottom-up approach on tryptic glycopeptides.
The detailed analysis of the glycopeptide takes advan-
tage of a unique dual-collision-cell design of the instru-
ment combined with ion-mobility separations to per-
form a time-aligned-parallel (TAP) fragmentation of
glycopeptides, in which information on the glycan
sequence and the glycosylation site is simultaneou-
sly obtained. The results demonstrate the benefit of
enabling dual-stage fragmentation where the indepen-
dently controlled collision induced dissociation pro-
vides an increase in the information obtained for site-
specific characterization of the glycopeptide. Since the
detailed characterization on the glycosylation heteroge-
neity can be performed on a single instrument platform
and within a short time, the approach is well suited for
lot-to-lot testing of production batches of MABs and for
fast elucidation of the glycosylation profiles.
Experimental
Chemicals and Reagents
All chemicals were of highest purity available. Dithio-
threitol (DTT), iodoacetamide (IAA), Tris-HCl, EDTA,
ammonium bicarbonate, and calcium chloride were
purchased from Sigma (St. Louis, MO, USA). Guanidine-
HCl was obtained from Pierce (Rockford, IL, USA).
2023J Am Soc Mass Spectrom 2009, 20, 2021–2033 ION-MOBILITY TOF-MS FOR LOT-TO-LOT HETEROGENEITYAnhydrous acetonitrile was from Fisher Scientific (Pitts-
burgh, PA, USA). Formic acid was obtained from EM
Sciences (Gibbstown, NJ, USA). Ultrapure water (18.2
M) was obtained from a Milli-Q water purifier (Milli-
pore Corporation, Medford, MA, USA). Sequencing-
grade porcine trypsin was obtained from Promega
Corp. (Madison, WI, USA). RapiGest SF was obtained
from Waters Corporation (Milford, MA, USA). Four
different batches (B0011, B1142, B2033, and B2045) of
trastuzumab (Herceptin) as a lyophilized powder were
purchased from Roche (Basel, Switzerland). This phar-
maceutical formulation contains additionally L-histidine
hydrochloride, L-histidine, --trehalose dihydrate and
polysorbate 20. Trastuzumab was dissolved in water for
injections according to the instruction from the manu-
facturer, resulting in a stock solution of 21 mg/mL. The
solution was diluted to 0.5 mg/mL with 50 mM ammo-
nium bicarbonate for intact mass analysis using ESI
Q-IM-TOF MS.
Reduction of Trastuzumab
Partial reduction of the IgG1 was performed according
to the following method [36, 37]: the trastuzumab stock
solution (4 L) was mixed with 66 L of 3 M Tris-HCl
buffer (pH 8.0) containing 1 mM EDTA to obtain a
working solution with 1.2 mg/mL of MAB. Two L of
1 M DTT (in 25 mM NH4HCO3) was added to the
solution, and the mixture was vortex mixed briefly
before incubation at 37 °C for 20 min. The reduction
was then quickly quenched with a 2% (vol/vol) formic
acid aqueous solution to a concentration of 0.11 mg/mL
(pH 3.0). The reduced sample was prepared daily
before analysis.
Preparation of Tryptic Glycopeptides
of Trastuzumab
An aliquot of trastuzumab stock solution (21 mg/mL)
was diluted with 8 M urea in 400 mM ammonium
bicarbonate to obtain a solution with 2.1 mg/mL of
trastuzumab. To this solution, a volume of 500 mM
EDTA in H2O was added. Trastuzumab was then
reduced with 10 mM DTT at 37 °C for 30 min, and
alkylated with 13 mM IAA in the dark at room temper-
ature for 45 min. The reduced and alkylated trastu-
zumab solution was further diluted by pure H2O to a
concentration of 0.5 mg/mL for trypsinization. Trypsin
digestion was performed overnight at 37 °C (trypsin/
protein ratio, 1:25, wt/wt). The digest was diluted to
0.015 mg/mL with 0.1% formic acid before injection.
Preparation of Released Glycans from Intact
Protein of Trastuzumab
A solution of Trastuzumab (4.5 mg/mL) was prepared
by diluting the stock solution (21 mg/mL) with a
solution of 0.1% (wt/vol) RapiGest in 50 mMNH4HCO3. The protein sample was reduced with 10
mM DTT for 45 min and alkylated with 20 mM iodoac-
etamide for 1 h. The enzyme PNGase F was added to
the sample, the solution was incubated overnight. The
released glycans were extracted by following the pub-
lished procedure [38], and were subsequently labeled
with 2-AB using the manufacturer protocols (Sigma).
Labeled glycans were purified by HILIC SPE (Waters
Corp.) and dried down. Approximately 50 pmol of
labeled glycans were loaded into Waters Glycan col-
umn (2.1  150 mm). The HILIC separation was done
with 0.5% formic acid in H2O (mobile phase A) and
0.5% FA in acetonitrile (0.22% B/min.).
Mass Spectrometry
All experiments were performed on a Waters Synapt
high definition mass spectrometer (HDMS) fitted with
an atmospheric pressure ionization electrospray source
(Waters Corporation, Milford, MA, USA). Detailed de-
scriptions of the instrument can be found elsewhere [37,
39, 40]. The instrument was operated in positive-ion
mode with a capillary voltage of 3.0 kV unless stated
otherwise. The ion source block and nitrogen desolva-
tion gas temperatures were set to 100 °C and 250 °C,
respectively, unless stated otherwise. The desolvation
gas was set to a flow rate of 250 L/h. The cone voltage
was maintained at 60 V for intact mass analysis. The
quadrupole was operated in nonresolving mode to
transmit a wide m/z range. Full-scan data for proteins
and tryptic digests were acquired over m/z range of 500
to 4000 or 50 to 1990, respectively. Data collection and
processing were controlled by MassLynx 4.1 software
(Waters Corp.). The deconvolution of ESI mass spectra
of intact/reduced proteins was performed using the
MaxEnt1 algorithm in the MassLynx software.
Analysis of Intact Trastuzumab and Trastuzumab
Subunits by LC/MS
An ACQUITY UPLC system (Waters Corp.) equipped
with a binary solvent manager, a sample manager, and
a column heater was directly coupled to a Synapt
HDMS mass spectrometer using a standard ESI inter-
face for all the analyses. Reversed-phase (RP) desalting
of intact and reduced antibody was performed on a
phenyl desalting column, (2.1  5 mm, 20 m, Waters
Corp). Mobile phase A was 0.1% formic acid in water,
mobile phase B was 0.1% formic acid in acetonitrile. For
intact trastuzumab analysis, the column was first
washed isocratically for 0.5 min at 5% B at a flow rate of
0.5 mL/min to remove all the salts and other contami-
nants in the samples. The antibody was then eluted
using a 1.5 min gradient (5% to 90% B) at a flow rate of
0.2 mL/min and a column temperature of 80 °C. Fol-
lowing each experiment, three additional rapid gradi-
ent cycles (0.5 ml/min and between 5 and 90% B) were
applied to condition the column to pre-injection state
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analysis is 4 min. For the LC/MS analysis of partially
reduced trastuzumab samples, a different gradient
(10% to 50% B in 7 min) was used to achieve maximized
chromatographic separation of the light and heavy
chains on the desalting column. The mass spectrometer
was calibrated externally using CsI (2 mg/mL) dis-
solved in 50% isopropanol. Analysis of intact trastu-
zumab was performed with a capillary voltage of 2.0
kV, sample cone of 60 V, m/z range of 1000 to 4000, and
mass resolution of 10,000 (V mode). For trastuzumab
subunits, the data were collected with a capillary volt-
age of 2.8 kV, sample cone of 35 V, m/z range of 600 to
3500, and mass resolution of 10,000. The MS ion source
and desolvation temperatures were set at 100 and
350 °C, respectively, for the experiments. The desolva-
tion gas flow rate was set to 600 L/h at the source and
desolvation temperatures discussed above. All four
batches of trastuzumab were analyzed by the exactly
same experimental settings with the same amount of
materials injected. The parameters used for MaxEnt1
deconvolution of the MS data from the heavy chain are
the following: input mass (m/z) range: 995–1995; output
mass range: 46,000–5,000; output data resolution: 1
Da/channel; model: uniform Gaussian with peak width
at half height 0.6; minimum intensity ratios: 30% (left
and right); complete iteration: convergence.
Analysis of Glycopeptides by nanoLC/MS/MS
To illustrate the possibilities of a full structural elucida-
tion of the glycan moieties one batch of trastuzumab
was chosen (B0011). The analyses of glycopeptides from
this batch were performed on the Synapt HDMS mass
spectrometer coupled with a nanoAcquity (Waters
Corp.) system. Tryptic peptides of trastuzumab (1.4
pmol) were separated by a reversed-phase column
(Atlantis C18, 3.5 m, 0.3  100 mm; Waters Corp.).
Peptides were eluted at 10 L/min with a linear gradi-
ent profile consisting of 3% to 40% B over 60 min, where
Solvent A was water containing 0.1% (vol/vol) formic
acid and Solvent B was acetonitrile containing 0.1%
(vol/vol) formic acid.
The LC elution time and the m/z value of glycopep-
tides were measured by operating the mass spectrom-
eter in TOF mode using a method described previously
[37, 41]. Briefly, as the peptides were eluted off the
column, MS data were acquired in a continuous fashion
by alternating low and elevated energies of the TRAP
cell so all the peptides eluting from the HPLC column
as well as the corresponding fragmented ions were
recorded simultaneously. A scan time of 1.0 s was set
for both low-energy (MS) data acquisition and elevated-
energy (MSE) spectra. During the low-energy scan,
intact peptide mass spectra were obtained by keeping
collision cell energy at 4 V, while the multiplex frag-
mentation MSE spectra were obtained by ramping col-
lision cell energies from 15 to 35 V. Both low-energymass spectra and elevated-energy spectra were ac-
quired in the m/z range of 50 to 1990.
Fragmentation of glycans and glycopeptides was
performed by operating the instrument in the mobility-
TOF mode. The instrument was set to perform MS/MS
analysis of glycopeptides at the LC elution time deter-
mined in the previous run. Each glycopeptide was
sequentially selected by the quadrupole and frag-
mented in the TRAP cell at the energy optimized for
glycan fragmentation (collision energy set at 35 V). The
fragment ions generated in the TRAP T-wave collision
cell of Synapt HDMS were then transported into the
IMS T-wave where ions were separated into individual
packets on the basis of their ion mobility (combination
of size, shape and charge as well as mass). The ion-
mobility separated fragment ions were subsequently
transported through the TRANSFER T-wave collision
cell in which the collision energy was alternated be-
tween two settings (low and high). When the collision
energy of the TRANSFER T-wave is set at a low-energy
(normally at 5 V), no additional fragmentation takes
place in the TRANSFER T-wave. Fragment ions ob-
served in this scan would only represent the fragments
generated in the TRAP T-wave. Thus MS/MS data
recorded in this process would contain information
only for the deduction of the glycan sequence of the
glycopeptides. To obtain the fragmentation of peptide
backbone, the collision energy of the TRANSFER T-
wave is increased to a higher energy (typically 60 to 100
V) in the second scan, and the ion-mobility separated
product ions are subjected to a second-generation frag-
mentation at which peptide backbone cleavage would
occur, and thus producing data for the deduction of
peptide sequence and glycosylation sites.
MS/MS data from the same precursor were com-
bined, smoothed, background-subtracted, and decon-
voluted to collapse the isotope peaks using the MaxEnt
3 program in the MassLynx software. MaxEnt3 pro-
cesses a spectrum with peaks in several charge states
and produces a simplified spectrum consisting of only
singly charged monoisotopic peaks. The spectrum gen-
erated from this process was either interpreted manu-
ally (for glycan sequence information) or submitted to a
de novo sequencing software (BioLynx) for the final
peptide sequence deduction.
Results and Discussion
Analysis of Intact Trastuzumab
Figure 1a shows the charge state distribution of trastu-
zumab from batch B2033. When the spectrum is exam-
ined in greater detail as in Figure 1b where the 53
charge state is shown, it can be observed that each
charge state consists of multiple peaks. When this
spectrum is deconvoluted (Figure 1c) the glycosylation
heterogeneity of the MAB is shown. The average theo-
retical mass of the G0F/G0F glycoform calculated from
the amino acid sequence [2, 42] is 148,057 Da. The
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difference of 2 Da. The theoretical mass calculation does
not take into consideration any other possible post-
translational modification, such as C-terminal amide
formation from glycine or pyroglutamic acid formation
from glutamic acid at the N-terminal since no addi-
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Figure 1. (a) ESI-TOF MS spectra of intact trastuzumab (batch
B2033) by LC-MS. Charge state distribution. (b) Zoomed spectrum
for the 53 charge state. (c) Deconvoluted mass spectrum show-
ing an overview of the glycosylation heterogeneity and comparing
batches B0011 (black), B1142 (green), B2033 (red), and B2045
(purple) by superimposing the spectra.tional information indicates these post-translation mod-ifications have occurred with the trastuzumab sample.
The measured mass on the IMS-Q-TOF instrument
represents a mass error of 13 ppm (externally cali-
brated) and is closer to the theoretical masses compared
with the data reported in other papers on different
types of mass spectrometers. Le and Bondarenko [43]
found a mass of 148,098 Da using an ion trap mass
spectrometer, and using a triple quadrupole instru-
ment, we found a mass of 148,066 Da [44] for the same
MAB.
Based on the deconvolution masses, peaks observed
in Figure 1c can be assigned to known glycoforms of the
trastuzumab antibodies: G0/G0F (147920 Da), G0F/
G0F (148059 Da), G0F/G1F (148,216 Da), G0F/G2F or
G1F/G1F (148,376 Da), G1F/G2F (148,535 Da), and
G2F/G2F (148,680 Da). Additional peaks, which are not
explicable with the most common glycan structures,
could be artifacts from the deconvolution process. To
validate whether these peaks have a connection with
the glycan heterogeneity, the sample was reduced to
generate subunits which were analyzed in the next step.
Deconvoluted mass spectra for intact trastuzumab
for all four batches are normalized and displayed in
Figure 1c. The spectra clearly reveal the glycoprofile
difference between trastuzumab antibodies from differ-
ent batches. The observed differences among the
batches are experimentally significant since multiple
injections of each sample yielded identical results. Fig-
ure 1c reveals that all batches contain equal number of
peaks (glycoforms), however, the intensity of each
corresponding peak varies greatly among the four
batches. The variability is attributed to the microhetero-
geneity, predominantly galactose heterogeneity, at the
conserved N-linked glycosylation site in the Fc region
of the antibody. It is well-known that N-linked oligo-
saccharides can vary during antibody processing.
Analysis of Trastuzumab Subunits
Reduction of the intact trastuzumab with DTT and
subsequent LC/MS allows mass analysis of light chain
and heavy chain subunits from a single injection. Figure
2a shows a typical total ion current (TIC) chromatogram
of the partially reduced sample desalted with the phe-
nyl desalting column. Two prominent peaks are shown,
each representing the light chain and the heavy chain.
The light chain is eluted of the column first (Rt  11.19
min) followed by the heavy chain (Rt  13.37 min).
When the TIC chromatograms of all four batches are
superimposed, no differences between batches can be
observed. Figures 2b and d show the examples of the
summed ESI raw spectra of the light chain and heavy
chain from reduced trastuzumab, and the deconvoluted
spectra for the light and the heavy chain are also shown
in Figures 2c and e.
Deconvoluted spectra for the light chain (Figure 2c)
consists of a major peak at 23,438 Da and two minor
peaks at 23,420 and 23,600, respectively. Based on the
theoretical mass calculation, the major peak at 23,438
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small peak at 23,420 Da probably results from the loss of
water from the light chain molecule. The observed mass
difference between the major peak and the minor peak
at 23,600 is 162 Da corresponding to a single hexose
modification of the light chain. This last structure could
not be observed when analyzing trastuzumab at the
intact protein level (Figure 1c), demonstrating that the
analysis of the reduced MAB has additional value over
intact protein analysis. In general, no differences be-
tween the different trastuzumab batches can be ob-
served with respect to the light chain of the molecule.
In contrast, significant microheterogeneity was
found to reside in the heavy chains. This observation is
expected as the presence of oligosaccharides is predom-
inantly located within the Fc region of the molecule.
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Figure 2. On-line LC/MS analysis of the partia
ion chromatogram of the reduced trastuzumab.
(Rt  11.2 min). (c) Deconvoluted mass spectr
spectrum of the heavy chain (Rt  13.4 min). (e)
(c), and (e) compare the different batches B0011 (
by superimposing chromatograms or the spec
artifacts.The deconvoluted spectrum of the heavy chain (Figure2e) shows two major peaks at 50,592 and 50,754 Da and
two minor peaks at 50,446 and 50,916 Da. Additionally,
there are several extraneous peaks observed in the
deconvoluted spectra in Figures 2c and e (marked with
an asterisk). These putative peaks are believed to be
deconvolution artifacts as they were not visible on the
original ESI mass spectra. Furthermore, the mass and
peak intensity of these peaks change when deconvolu-
tion parameters (peak widths at half height) were
modified. Several deconvolution artifacts and their
sources have been reported previously in the literature
[23]. The two major peaks in Figure 2e (50,592 and 50,754
Da) have a characteristic mass difference of 162 Da,
consistent with the heavy chain glycosylations where the
core glycan structures from the variants differ from each
other by a galactose residue. The minor peak with a mass
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tra,of 50,916 also has a mass difference of 162 Da, correspond-
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a mass of 50,445 Da differs 146 Da from the major peak of
50,592 Da, implying that the heavy chain contains an
oligosaccharide moiety without fucose.
The spectra of the heavy chains from the four batches
of trastuzumab are compared. The peak intensities were
summed and set to 100%. The amounts of the different
glycoforms were calculated as percentage of the total
peak intensities. Although the overall glycoform pat-
terns are very similar, it is found that the peak intensity
is varied for each of the corresponding glycoform. Table
1 summarizes the relative abundances of G0, G0F, G1F,
and G2F forms for all four production batches of
trastuzumab. The relative quantification of the glyco-
forms was calculated based on the peak intensities of
the deconvoluted mass spectra of the heavy chain
(Figure 2e). These values agree well with the results
obtained from 2-aminobenzamide labeled released gly-
cans from the same batch sample (see Supplemental
Materials for batch B2045, which can be found in the
electronic version of this article). To check the repro-
ducibility of the method, batch B0011 and B2033 were
reduced and analyzed on five different days with
multiple injections. The results show that the analysis is
reproducible within the day and also between days. The
relative standard deviation (RSD) for peak intensity is
generally about 5% with exception of the glycoform G0,
which shows a relatively larger variation (20%). This
large variation is attributed to the low peak intensity
observed for the G0 form. It is the least intensive peak
among all the glycoforms. As the RSD values are very
low, the results in Table 1 clearly show that there are
variations in glycosylation profile between the batches.
In batches B0011 and B1142 the G0F glycan is the most
prominent form, however in batch B2045, the G1F
glycoform is the most prominent one. For Batch B2033,
the intensities between glycoform G0F and G1F are
approximately equal. Batch B2033 shows the highest G0
percentage compared with the other three batches, and
batch B2045 shows more G2F glycoform exists to this
preparation compared with the other three batches.
These results demonstrate the application of the
described method for the lot-to-lot comparison of the
glycosylation profile of a therapeutic monoclonal anti-
body. The mentioned glycoforms, however, are only
determined by deconvoluting the spectrum of intact and
Table 1. Comparison of the four trastuzumab batches for the
relative abundance of G0, G0F, G1F, and G2F glycans measured
on the deconvoluted ESI mass spectrum of the heavy chain
(Figure 2)
Batch
Glycoforms of heavy chain (%)
G0 G0F G1F G2F
B0011 4.96 52.8 35.8 6.47
B2033 9.59 39.8 40.0 10.6
B1142 6.53 47.4 38.4 7.65
B2045 6.12 35.9 44.7 13.3reduced trastuzumab and by searching for the most
common glycoforms. No real structural elucidation was
performed. For the structural characterization of the gly-
coforms of trastuzumab the reduced molecule was made
smaller again and was subject to a trypsin digestion.
Characterization of Glycopeptides
To further elucidate the glycan sequencing and to
determine the glycosylation site for the glycosylation
observed at the intact or the subunit level, the method
developed by Olivova et al. [37] was adapted in this
work. The method essentially includes two sequential
steps to characterize glycopeptides from trastuzumab
digestion without any glycopeptide enrichment. In the
first step, the LC elution time and the precursor mass of
the glycopeptides are determined by a multiplexed
parallel fragmentation method. In the second step, the
glycan sequence, as well as the glycopeptide backbone
sequence, is determined for all the glycopeptides re-
vealed in the first step.
Among all the tryptic peptides of trastuzumab, the
overwhelming majority of the tryptic peptides are not
glycosylated. Since there is no prior enrichment in-
volved, the first step in the analysis was to identify the
peptide that is glycosylated as well as their elution time.
Under ESI conditions, mass spectral detection of glyco-
peptides during on-line LC/MS analysis is normally
achieved by precursor ion scanning or cone fragmenta-
tion for reporter oxonium fragment ions (e.g., m/z
204.087) derived from glycan fragments [45, 46]. To
obtain high specificity of precursor-ion scanning, it is
pivotal to use high-resolution, high accuracy fragment
ion selection on a hybrid quadrupole time-of-flight
(Q-TOF) mass spectrometer [37, 47].
The multiplexed parallel fragmentation method
takes advantage of the high mass accuracy that a Q-TOF
mass spectrometer offers in precursor ion scanning. The
precursor masses of peptides eluting off the RP column
were obtained in a low-energy scan in which peptides
were not fragmented. In the following scan, the colli-
sion energy was increased to a level such that only the
fragmentation of glycan moiety of the glycopeptide was
induced. It is known that glycans are labile, and less
collision energy is required to induce the cleavage of the
glycosidic bonds compared with that of the peptide
backbone. This step of fragmentation produced oxo-
nium ions while minimizing peptide backbone cleav-
age. The appearance of oxonium ions marked the
elution time of glycopeptides. The intact mass of the
glycopeptides were acquired from the low-energy scan.
Because there was no precursor selection at the elevated
energy stage, all the eluting peptides were subjected to
the same collision condition. However, only glycopep-
tides produced glycan reporter ions. This data acquisi-
tion procedure was repeated across the whole LC
gradient.
Figure 3 shows LC/MS chromatograms from the
analysis of a tryptic digest of trastuzumab (batch B0011)
z 204
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Figure 3a depicts the MS responses of tryptic peptides
at low collision energy during the LC gradient run.
Figure 3b shows the responses of the peptides at the
elevated energy, and Figure 3c displays the recon-
structed ion chromatogram for oxonium ions (m/z
204.084 and 366.139) from the elevated energy data. The
dominant peak at retention time of 17.79 min is attrib-
uted to the co-eluting (Figure 3c) glycopeptides. To
identify all the precursors responsible for the genera-
tion of oxonium ions, scans spanning the elution time of
oxonium ions are summed for both low- and high-
energy data and presented in Figures 4a and b, respec-
tively. Comparison of Figure 4a and b reveals that the
signal intensities of several peaks in the m/z range
between 800 and 1000 decreased in the elevated-energy
spectrum. The mass difference of the four peaks (la-
beled by *), which are triply charged (m/z 829.96, 878.66,
932.68, 986.70), matches the glycoform patterns ob-
served in the intact and reduced trastuzumab analyses,
suggesting the four glycopeptides contain the same
peptide backbone and represent the G0, G0F, G1F, G2F
glycoforms of the glycopeptides. These four different
masses were selected as the precursors for the second
step of the experiment.
Peaks corresponding to the doubly charged species
of the four glycopeptides are also observed in both low
and high-energy scans (m/z 1244.52 1317.49, 1398.55,
1479.58, and all labeled by [filled square]). Each of these
peaks shows similar ion intensity in the elevated energy
Figure 3. LC/MS/MSE analysis of a tryptic d
intensity chromatograms for the tryptic precurso
of the two acquisition channels: (a) LC-MS, Lo
structed ion chromatogram for oxonium ions (m/data compared with the low-energy data, suggestinglittle fragmentation taking place for the doubly charged
glycopeptides under the relatively low collision energy
setting. It is known that less energy is needed to
fragment the same species with higher charge states.
The other peaks observed in the spectra (e.g., m/z:
1134.92, 1215.97) come from glycopeptides with trun-
cated glycan moieties in comparison with the G0, G0F,
G1F, G2F glycoforms. These species were generated
from the fragmentation of the glycopeptides precursor
ions.
Although only ions with 3 charge states were
fragmented predominantly in the multiplexed parallel
fragmentation approach, the data clearly shows good
sensitivity and selectivity in identifying glycopeptides
for further characterizations. The MS sensitivity is as-
cribed to that fact the co-eluting glycopeptides all
contributed to the overall signal intensity of oxonium
ions. The selectivity comes from the collision energy
settings, which are below the typical energy used for
the fragmentation of the peptide backbone, and the
formation of potentially interfering fragment ions is
considerably reduced. As a result, the formation of the
reporter fragment ions is purely generated by glycan
fragmentation. The low collision energy settings em-
ployed were distinct frommost other types of precursor
ion scanning methods used for the identification of
protein modifications that require higher collision en-
ergies to generate the reporter fragment ion of interest.
The determination of the molecular masses and
retention times for these glycopeptides allow us to
of trastuzumab (batch B0011). The base peak
d associated fragment ions are provided in each
ergy; (b) LC/MSE, elevated energy; (c) recon-
.084 and 366.139) from the elevated energy data.igest
rs an
w-enfocus only on the glycopeptides of interest for the
min
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site. Each of the four protonated glycopeptides was se-
quentially selected by the quadrupole ion filter and
subsequently fragmented in the TRAP cell with energy
sufficient to induce extensive glycan fragmentation
while peptide backbone cleavage was kept at mini-
mum. The fragment ions were then transported into the
ion-mobility cell where ions were separated into indi-
vidual ion packages on the basis of their ion mobility
(combination of size, shape, and charge as well as
mass). A two-dimensional plot of ion drift time versus
the m/z values from a glycopeptide (m/z 932.68), which
is fragmented in the TRAP cell, followed by ion mobil-
ity separation is shown in Figure 5a. The ion-mobility
separated fragment ions were subsequently transported
through the TRANSFER T-wave collision cell in which
the collision energy was alternated between two set-
tings (low and high). When the collision energy of the
TRANSFER cell is set at a low-energy (normally at
5 V), no additional fragmentation takes place in the
TRANSFER T-wave. Fragment ions observed in this
scan would only represent the fragments generated in
the TRAP T-wave collision cell. Thus MS/MS data
recorded in this process would contain information
only for the deduction of the glycan sequence of the
glycopeptides. Figure 5b shows a summed MS/MS
spectrum from a glycopeptide (m/z 932.68) fragmented
in the TRAP cell as a representative example for all the
glycopeptides investigated. Multiply charged ions in
the raw data were transformed to singly charged ones
using MaxEnt3. From Figure 5b, it can be seen that
fragmentation of the peptide backbone under the cho-
Figure 4. ESI mass spectra of glycopeptides f
mass spectrum for the retention time at 17.8 mi
ion mass spectrum for the retention time at 17.8sen conditions is negligible. The MS/MS spectrumexclusively exhibits the cleavage of glycosidic linkages,
thus revealing information on the glycan moiety. On the
basis of the fragment ion analysis, the general structure
of an N-linked complex type biantennary glycan could
be deduced and confirmed [10].
Mass analysis on the fragment ions generated in the
TRAP T-wave collision cell shows the existence of a
fragment ion with a m/z value of 1392.57. This ion
comes from a peptide that contains a single HexNAc
attached to the glycosylated residue of the N-glycopeptide.
To obtain the fragmentation of this precursor, the
collision energy of the TRANSFER T-wave was in-
creased to a higher energy (typically 80 to 120 V) in the
second scan, and the ion-mobility separated product
ions are subjected to a second-generation fragmentation
at which peptide backbone cleavage would occur. Fig-
ure 6a shows the corresponding data (in DriftScope
software, Waters Corp., Milford, MA, USA) obtained
from the N-glycopeptide fragments after the collision
energy of the TRANSFER T-wave was raised up to 100
V. Figure 6b displays the mass spectrum that is gener-
ated by combining all the fragmentation data from drift
time 7.2 to 8.3 ms. Since these product ions all share the
same drift time as the precursor ion (m/z 1392.57, see
Figure 5a), these fragment ions all come from the same
precursor, and the reconstructed spectrum over that
range of drift times corresponds to the peptide se-
quence of the precursor. From Figure 6b, the peptide
sequence (EEQYNSTYR) can be easily confirmed, and
the glycan attachment site is inferred.
The approach to fragment mobility-separated prod-
uct ions using the instrument is rather similar to an MS3
C/MS/MSE analysis. (a) Combined precursor
the low-energy scan. (b) Combined fragment
from the elevated energy scan.rom L
n fromtype experiment performed on an ion-trap mass spec-
quen
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all first- and second-generation product ions are re-
corded in parallel. In addition, the two-step sequential
fragmentation process allows a user to optimize the
collision energy for glycosidic and peptide fragmenta-
tion separately to maximize the information obtained in
each step by avoiding the loss of glycan sequence
information due to the higher energy applied for pep-
tide backbone fragmentation. The ability to reduce
collision energy applied specifically for glycosidic frag-
mentation minimizes the peptide backbone fragment
ions that can complicate the interpretation of glycan
sequences. Because the process de-couples the glycan
fragmentation process from peptide backbone fragmen-
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%
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Figure 5. Glycopeptides analysis using LC/ES
drift time versus the m/z values for the [M
fragmentation in the TRAP cell, followed by ion
the drift-time span for the fragment ion with m/
3H]3 ion at m/z 932.70 from Figure 4. The frag
TRAP cell to yield information on the glycan setation, it is conceivable that this approach can be usedfor different sizes/types of glycopeptides including
O-linked glycopeptides.
The elucidated glycan structures matched the G0,
G0F, G1F, and G2F forms reported in literature [48].
Although no novel glycan structure is discovered, the
ability to rapidly obtain glycoprofile of a therapeutic
monoclonal antibody and subsequently confirm the
glycan structures is very much needed in the biophar-
maceutical industry. Blocking HER2 by trastuzumab is
mediated by the antigen-binding site of the mAb and
may contribute to some or all of the observed clinical
efficacy of these agents. However, clinical efficacy may
also be a result of, at least in some part, antibody-
specific mechanisms mediated through the Fc domain
mass
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gion
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cell-mediated phagocytosis (ADCP). The presence of
‘core’ oligosaccharide is essential for the expression of
IgG-Fc effector functions, and the addition of galactose
residues has a variable influence on the efficacy of
specific functions [5]. The presence or absence of galac-
tose on IgG glycans correlates in some but not all
monoclonal IgG antibodies with respect to the binding
to the Fc receptor [48]. The impact of the presence of
galactose and fucose residues on the binding of trastu-
zumab to Fc receptors has not been reported. However,
it is striking that we found a difference in galactose
residues between different production lots for a mAb,
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Figure 6. Obtaining the N-glycosylation site
product ions generated in the TRAP T-wave. (a) T
the second generation of fragment ions followin
boxed highlight region represents the distributi
precursorm/z 1392.58 as shown in DriftScope (note
(b) Reconstructed MS spectrum from the boxed rewhich is already registered.Therefore, further study is required to demonstrate if
there is any correlation between the drug efficacy and
the lot-to-lot differences in glycoprofile. This work,
however, provides an example of how the ESI-Q-IM-
TOF platform can be used for lot-to-lot consistency
testing and structural elucidation of glycans when new
MABs are developed.
Conclusions
In this work, we have presented a rapid method to
distinguish the lot-to-lot heterogeneity in glycosylation
profile of the commercially available monoclonal anti-
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the pbody trastuzumab. The batches were first compared at
2032 DAMEN ET AL. J Am Soc Mass Spectrom 2009, 20, 2021–2033the intact level, showing differences between the four
production batches tested. A subsequent analysis of the
reduced antibody allowed for additional confirmation
of the glycoprofile difference. In addition, by using the
unique ion-mobility functionality of the instrument, the
structures of the glycan moieties are confirmed in a
simple experiment. The results demonstrate the current
analytical method is very effective for monitoring and
validating the glycan variations of production lots dur-
ing the process of antibody development. The FDA and
other regulatory agencies may require more data on the
analytical characterization of MABs in the future and
this platform is suitable to fulfill these needs. Lot-to-lot
consistency testing is important because molecular het-
erogeneity of MABs may affect stability and potency.
Appendix A
Supplementary Material
Supplementary material associated with this article
may be found in the online version at doi:10.1016/
j.jasms.2009.07.017.
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